Volume | 246,812 |
|
|||||
News | - | ||||||
Day High | 10.78 | Low High |
|||||
Day Low | 10.01 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inovio Pharmaceuticals Inc New | INO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.42 | 10.01 | 10.78 | 10.16 | 10.37 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,736 | 246,812 | $ 10.36 | $ 2,556,229 | - | 3.888 - 14.748 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:03:34 | 30 | $ 10.05 | USD |
Inovio Pharmaceuticals Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
235.81M | 23.37M | - | 832k | -135.12M | -5.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inovio Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.64 | 11.25 | 9.285 | 10.40 | 407,629 | 0.52 | 5.39% |
1 Month | 12.38 | 14.748 | 8.35 | 11.66 | 420,648 | -2.22 | -17.93% |
3 Months | 5.84 | 14.748 | 4.73 | 9.82 | 491,453 | 4.32 | 73.97% |
6 Months | 5.04 | 14.748 | 3.888 | 7.17 | 2,073,076 | 5.12 | 101.59% |
1 Year | 10.2324 | 14.748 | 3.888 | 6.62 | 4,203,276 | -0.0724 | -0.71% |
3 Years | 82.80 | 123.96 | 3.888 | 35.41 | 4,939,495 | -72.64 | -87.73% |
5 Years | 46.56 | 426.00 | 3.888 | 121.97 | 9,187,037 | -36.40 | -78.18% |
Inovio Pharmaceuticals Description
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. |